文献速递肾癌与肾肿瘤

立体定向消融放疗治疗原发性肾癌的2期试验

Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.
PubMed 文献 · Eur Urol · 2023-03-08

这项2期试验纳入16例活检证实、影像学增大的≤5 cm原发性肾细胞癌患者,接受3次12 Gy或5次8 Gy的立体定向消融放疗。1年局部控制率为94%(15/16),所有患者均有病理缓解证据,无≥2级毒性,但平均肾小球滤过率从基线65.6降至1年时55.4 ml/min。

要点

  • 1年影像学局部控制率为94%(15/16;95%CI 70–100)。
  • 中位治疗前肿瘤生长速率0.8 cm/年降至治疗后0.0 cm/年(p<0.002)。
  • 无≥2级急性或晚期毒性,平均肾小球滤过率1年时下降。

核心结论

  • 本临床试验为支持立体定向消融放疗对原发性肾细胞癌有效的证据增添了新内容,支持其在对照性3期临床试验中评估。

研究设计与样本

  • 2期试验,纳入活检证实、影像学增大的≤5 cm原发性肾细胞癌患者,共16例不同族裔患者;立体定向消融放疗采用3次12 Gy或5次8 Gy分割。

主要发现

  • 1年影像学局部控制率为94%(15/16;95%CI 70–100)。
  • 全部患者均有病理缓解证据(透明变性、坏死和肿瘤细胞密度降低)。
  • 按RECIST 1.1标准,1年时100%的病灶无进展。
  • 中位治疗前生长速率为0.8 cm/年(IQR 0.3–1.4),中位治疗后生长速率为0.0 cm/年(IQR -0.4–0.1;p<0.002)。
  • 肿瘤细胞活力从4.6%降至1年时0.7%(p=0.004);删失患者中位随访36个月时疾病控制率为94%。

关键数值与推荐

  • 无≥2级急性或晚期毒性。
  • 平均肾小球滤过率从基线65.6 ml/min降至1年时55.4 ml/min(p=0.003)。
  • 空间蛋白和基因表达分析与放疗诱导细胞衰老一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most renal cell carcinomas (RCCs) are localized and managed by active surveillance, surgery, or minimally invasive techniques. Stereotactic ablative radiation (SAbR) may provide an innovative non-invasive alternative although prospective data are limited. OBJECTIVE: To investigate whether SAbR is effective in the management of primary RCCs. DESIGN, SETTING, AND PARTICIPANTS: Patients with biopsy-confirmed radiographically enlarging primary RCC (≤5 cm) were enrolled. SAbR was delivered in either three (12 Gy) or five (8 Gy) fractions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was local control (LC) defined as a reduction in tumor growth rate (compared with a benchmark of 4 mm/yr on active surveillance) and pathologic evidence of tumor response at 1 yr. Secondary endpoints included LC by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1), safety, and preservation of kidney function. Exploratory tumor cell-enriched spatial protein and gene expression analysis were conducted on pre- and post-treatment biopsy samples. RESULTS AND LIMITATIONS: Target accrual was reached with the enrollment of 16 ethnically diverse patients. Radiographic LC at 1 yr was observed in 94% of patients (15/16; 95% confidence interval: 70, 100), and this was accompanied by pathologic evidence of tumor response (hyalinization, necrosis, and reduced tumor cellularity) in all patients. By RECIST, 100% of the sites remained without progression at 1 yr. The median pretreatment growth rate was 0.8 cm/yr (interquartile range [IQR]: 0.3, 1.4), and the median post-treatment growth rate was 0.0 cm/yr (IQR: -0.4, 0.1, p < 0.002). Tumor cell viability decreased from 4.6% to 0.7% at 1 yr (p = 0.004). With a median follow-up of 36 mo for censored patients, the disease control rate was 94%. SAbR was well tolerated with no grade ≥2 (acute or late) toxicities. The average glomerular filtration rate declined from a baseline of 65.6 to 55.4 ml/min at 1 yr (p = 0.003). Spatial protein and gene expression analyses were consistent with the induction of cellular senescence by radiation. CONCLUSIONS: This clinical trial adds to the growing body of evidence suggesting that SAbR is effective for primary RCC supporting its evaluation in comparative phase 3 clinical trials. PATIENT SUMMARY: In this clinical trial, we investigated a noninvasive treatment option of stereotactic radiation therapy for the treatment of primary kidney cancer and found that it was safe and effective.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Hannan R, McLaughlin MF, Pop LM, et al. Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer. Eur Urol. 2023. PMID: 36898872. doi:10.1016/j.eururo.2023.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。